October 9, 2014Open Access

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Ayalew TefferiThe Wistar Institute TLTerra L. LashoMayo Clinic ATAlexander TischerMayo Clinic

Key Points

Key points are not available for this paper at this time.

Abstract

To the editor: Approximately 90% of patients with primary myelofibrosis (PMF) harbor JAK2 (58%), CALR (25%), or MPL (7%) mutations.11⇓2-33 CALR -mutated PMF patients are younger than their JAK2 -mutated counterparts, and they display higher platelet count, lower leukocyte count,

AIに質問

Bookmark

View Full Paper